Eligible patients with symptomatic PAD or with a history of peripheral artery revascularization should be prescribed antiplatelet monotherapy for secondary prevention of both cardiovascular and limb events, using aspirin, clopidogrel, and/or vorapaxar. Given the significant overlap of PAD and coronary artery disease, the evidence presented in this article may have important implications for management of patients with coronary artery disease.
- Antiplatelet therapy
- Endovascular revascularization
- Peripheral artery disease
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine